{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:10:43Z","timestamp":1794265843010,"version":"4.9.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.antiviral.2020.104732","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T08:16:21Z","timestamp":1581927381000},"page":"104732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["The direct and indirect consequences of cytomegalovirus infection and potential benefits of vaccination"],"prefix":"10.1016","volume":"176","author":[{"given":"Paul","family":"Griffiths","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.antiviral.2020.104732_bib1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1086\/421999","article-title":"Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee","volume":"39","author":"Arvin","year":"2004","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"10.1016\/j.antiviral.2020.104732_bib2","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/j.1600-6143.2012.04087.x","article-title":"Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy","volume":"12","author":"Atabani","year":"2012","journal-title":"Am. J. Transplant."},{"issue":"1","key":"10.1016\/j.antiviral.2020.104732_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.1958","article-title":"Criteria to define interruption of transmission of human cytomegalovirus from organ donor to recipient","volume":"28","author":"Baraniak","year":"2018","journal-title":"Rev. Med. Virol."},{"issue":"3","key":"10.1016\/j.antiviral.2020.104732_bib4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.antiviral.2020.104732_bib5","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How we treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.antiviral.2020.104732_bib6","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2003-10-3616","article-title":"The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy","volume":"103","author":"Boeckh","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.antiviral.2020.104732_bib7","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/infdis\/jix048","article-title":"Cytomegalovirus (CMV) DNA quantitation in bronchoalveolar lavage fluid from hematopoietic stem cell transplant recipients with CMV pneumonia","volume":"215","author":"Boeckh","year":"2017","journal-title":"J. Infect. Dis."},{"issue":"1\u20132","key":"10.1016\/j.antiviral.2020.104732_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2014.12.020","article-title":"Variation in the human immune system is largely driven by non-heritable influences","volume":"160","author":"Brodin","year":"2015","journal-title":"Cell"},{"issue":"25","key":"10.1016\/j.antiviral.2020.104732_bib9","first-page":"305","article-title":"Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men--New York City and California","volume":"30","year":"1981","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"6","key":"10.1016\/j.antiviral.2020.104732_bib10","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1073\/pnas.1424818112","article-title":"Structural and biochemical studies of HCMV gH\/gL\/gO and Pentamer reveal mutually exclusive cell entry complexes","volume":"112","author":"Ciferri","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2020.104732_bib11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-2334-7-71","article-title":"Incidence of cytomegalovirus infection among the general population and pregnant women in the United States","volume":"7","author":"Colugnati","year":"2007","journal-title":"BMC Infect. Dis."},{"issue":"4","key":"10.1016\/j.antiviral.2020.104732_bib12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0002-9610(98)00205-0","article-title":"Occult herpes family viruses may increase mortality in critically ill surgical patients","volume":"176","author":"Cook","year":"1998","journal-title":"Am. J. Surg."},{"issue":"6","key":"10.1016\/j.antiviral.2020.104732_bib13","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1086\/514145","article-title":"Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation","volume":"176","author":"Cope","year":"1997","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.antiviral.2020.104732_bib14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/(SICI)1096-9071(199706)52:2<200::AID-JMV14>3.0.CO;2-O","article-title":"Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation","volume":"52","author":"Cope","year":"1997","journal-title":"J. Med. Virol."},{"issue":"9427","key":"10.1016\/j.antiviral.2020.104732_bib15","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0140-6736(04)16500-8","article-title":"Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy","volume":"363","author":"Deayton","year":"2004","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.antiviral.2020.104732_bib16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/rmv.1862","article-title":"Cytomegalovirus latency and reactivation: recent insights into an age old problem","volume":"26","author":"Dupont","year":"2016","journal-title":"Rev. Med. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2020.104732_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1084\/jem.190.2.177","article-title":"The dynamics of human cytomegalovirus replication in vivo","volume":"190","author":"Emery","year":"1999","journal-title":"J. Exp. Med."},{"issue":"9220","key":"10.1016\/j.antiviral.2020.104732_bib18","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/S0140-6736(00)02350-3","article-title":"Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation","volume":"355","author":"Emery","year":"2000","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.antiviral.2020.104732_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004058","article-title":"Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation","volume":"10","author":"Fielding","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2020.104732_bib20","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.22206","article-title":"Control of immune ligands by members of a cytomegalovirus gene expansion suppresses natural killer cell activation","volume":"6","author":"Fielding","year":"2017","journal-title":"Elife"},{"issue":"10","key":"10.1016\/j.antiviral.2020.104732_bib21","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/cid\/cit083","article-title":"Seropositivity and higher immunoglobulin g antibody levels against cytomegalovirus are associated with mortality in the population-based European prospective investigation of Cancer-Norfolk cohort","volume":"56","author":"Gkrania-Klotsas","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.antiviral.2020.104732_bib22","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/sj.bmt.1701139","article-title":"Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor\/recipient serostatus, acute GVHD and CMV disease","volume":"21","author":"Gor","year":"1998","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"10.1016\/j.antiviral.2020.104732_bib23","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/path.4437","article-title":"The pathogenesis of human cytomegalovirus","volume":"235","author":"Griffiths","year":"2015","journal-title":"J. Pathol."},{"issue":"Pt 2","key":"10.1016\/j.antiviral.2020.104732_bib24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1099\/0022-1317-79-2-213","article-title":"Studies of viral co-factors for human immunodeficiency virus in vitro and in vivo","volume":"79","author":"Griffiths","year":"1998","journal-title":"J. Gen. Virol."},{"issue":"10","key":"10.1016\/j.antiviral.2020.104732_bib25","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1473-3099(12)70197-4","article-title":"Burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunisation","volume":"12","author":"Griffiths","year":"2012","journal-title":"Lancet Infect. Dis."},{"issue":"11\u201312","key":"10.1016\/j.antiviral.2020.104732_bib26","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0264-410X(00)00377-7","article-title":"Encouraging prospects for immunisation against primary cytomegalovirus infection","volume":"19","author":"Griffiths","year":"2001","journal-title":"Vaccine"},{"issue":"9773","key":"10.1016\/j.antiviral.2020.104732_bib27","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"issue":"8603","key":"10.1016\/j.antiviral.2020.104732_bib28","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(88)90685-X","article-title":"Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus","volume":"2","author":"Grundy","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2020.104732_bib29","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM196411122712001","article-title":"Infectious pulmonary disease in patients receiving immunosuppressive therapy for organ transplantation","volume":"271","author":"Hill","year":"1964","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.antiviral.2020.104732_bib30","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 Days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am. J. Transplant."},{"issue":"10","key":"10.1016\/j.antiviral.2020.104732_bib31","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/infdis\/jir060","article-title":"Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy","volume":"203","author":"Hunt","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.antiviral.2020.104732_bib32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1086\/515621","article-title":"Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data","volume":"178","author":"Ioannidis","year":"1998","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.antiviral.2020.104732_bib33","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02128-16","article-title":"Human cytomegalovirus (HCMV)-Specific CD4+ T cells are polyfunctional and can respond to HCMV-infected dendritic cells in vitro","volume":"91","author":"Jackson","year":"2017","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.antiviral.2020.104732_bib34","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1086\/379077","article-title":"Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome","volume":"37","author":"Kempen","year":"2003","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.antiviral.2020.104732_bib35","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1473-3099(11)70344-9","article-title":"A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Kharfan-Dabaja","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104732_bib36","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid organ transplantation","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.antiviral.2020.104732_bib37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.vaccine.2013.09.042","article-title":"Priorities for CMV vaccine development","volume":"32","author":"Krause","year":"2013","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.antiviral.2020.104732_bib38","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/rmv.664","article-title":"CMV in critically ill patients: pathogen or bystander?","volume":"20","author":"Limaye","year":"2010","journal-title":"Rev. Med. Virol."},{"issue":"8","key":"10.1016\/j.antiviral.2020.104732_bib39","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1001\/jama.2017.10569","article-title":"Effect of ganciclovir on IL-6 levels among cytomegalovirus-seropositive adults with critical illness: a randomized clinical trial","volume":"318","author":"Limaye","year":"2017","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.antiviral.2020.104732_bib40","article-title":"A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic-cell transplantation","author":"Ljungman","year":"2019","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.antiviral.2020.104732_bib41","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.cell.2018.06.028","article-title":"An unbiased screen for human cytomegalovirus identifies neuropilin-2 as a central viral receptor","volume":"174","author":"Martinez-Martin","year":"2018","journal-title":"Cell"},{"issue":"25","key":"10.1016\/j.antiviral.2020.104732_bib42","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.antiviral.2020.104732_bib43","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"12","key":"10.1016\/j.antiviral.2020.104732_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00380-17","article-title":"Transient oral human cytomegalovirus infections indicate inefficient viral spread from very few initially infected cells","volume":"91","author":"Mayer","year":"2017","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2020.104732_bib45","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz003","article-title":"Correlation of cytomegalovirus (CMV) disease severity and mortality with CMV viral burden in CMV-seropositive donor and CMV-seronegative solid organ transplant recipients","volume":"6","author":"McBride","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104732_bib46","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.bbi.2014.05.014","article-title":"Multiple latent viruses reactivate in astronauts during Space Shuttle missions","volume":"41","author":"Mehta","year":"2014","journal-title":"Brain Behav. Immun."},{"issue":"18","key":"10.1016\/j.antiviral.2020.104732_bib47","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM199204303261803","article-title":"A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation","volume":"326","author":"Merigan","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.antiviral.2020.104732_bib48","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM198801143180202","article-title":"Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation","volume":"318","author":"Meyers","year":"1988","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.antiviral.2020.104732_bib49","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/cid\/cix793","article-title":"Use of viral load as a surrogate marker in clinical studies of cytomegalovirus in solid organ transplantation: a systematic review and meta-analysis","volume":"66","author":"Natori","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104732_bib50","first-page":"CD005133","article-title":"Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients","volume":"2","author":"Owers","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.antiviral.2020.104732_bib51","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/tid.12542","article-title":"Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants","volume":"18","author":"Panagou","year":"2016","journal-title":"Transpl. Infect. Dis."},{"issue":"12","key":"10.1016\/j.antiviral.2020.104732_bib52","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.antiviral.2020.104732_bib53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/rmv.598","article-title":"Cytomegalovirus and human immunosenescence","volume":"19","author":"Pawelec","year":"2009","journal-title":"Rev. Med. Virol."},{"issue":"11","key":"10.1016\/j.antiviral.2020.104732_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081881","article-title":"Seroprevalence of cytomegalovirus, Epstein Barr virus and varicella zoster virus among pregnant women in Bradford: a cohort study","volume":"8","author":"Pembrey","year":"2013","journal-title":"PloS One"},{"issue":"8376","key":"10.1016\/j.antiviral.2020.104732_bib55","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(84)90930-9","article-title":"Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants","volume":"1","author":"Plotkin","year":"1984","journal-title":"Lancet"},{"issue":"8900","key":"10.1016\/j.antiviral.2020.104732_bib56","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0140-6736(94)91835-X","article-title":"Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group","volume":"343","author":"Prentice","year":"1994","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.antiviral.2020.104732_bib57","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/rmv.615","article-title":"Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir","volume":"19","author":"Prichard","year":"2009","journal-title":"Rev. Med. Virol."},{"issue":"24","key":"10.1016\/j.antiviral.2020.104732_bib58","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1001\/jama.1989.03420240121038","article-title":"The indirect effects of cytomegalovirus infection on the outcome of organ transplantation","volume":"261","author":"Rubin","year":"1989","journal-title":"J. Am. Med. Assoc."},{"issue":"15","key":"10.1016\/j.antiviral.2020.104732_bib59","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1056\/NEJM199104113241509","article-title":"Preemptive therapy in immunocompromised hosts","volume":"324","author":"Rubin","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.antiviral.2020.104732_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016103","article-title":"Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States","volume":"6","author":"Simanek","year":"2011","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.antiviral.2020.104732_bib61","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jcv.2008.07.012","article-title":"Cytomegalovirus seroprevalence and childhood sources of infection: a population-based study among pre-adolescents in the United States","volume":"43","author":"Staras","year":"2008","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2020.104732_bib62","series-title":"Vaccines for the 21st Century: a Tool for Decision Making","author":"Stratton","year":"2001"},{"issue":"8","key":"10.1016\/j.antiviral.2020.104732_bib63","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1128\/AAC.43.8.1941","article-title":"Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein","volume":"43","author":"Talarico","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5455","key":"10.1016\/j.antiviral.2020.104732_bib64","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.287.5455.1031","article-title":"Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40","volume":"287","author":"Tomasec","year":"2000","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.antiviral.2020.104732_bib65","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.100.1.61","article-title":"Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study","volume":"100","author":"Valantine","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.antiviral.2020.104732_bib66","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.14925","article-title":"A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor","author":"Vincenti","year":"2018","journal-title":"Am. J. Transplant."},{"issue":"11","key":"10.1016\/j.antiviral.2020.104732_bib67","doi-asserted-by":"crossref","first-page":"7570","DOI":"10.1073\/pnas.112680099","article-title":"UL40-mediated NK evasion during productive infection with human cytomegalovirus","volume":"99","author":"Wang","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"8654","key":"10.1016\/j.antiviral.2020.104732_bib68","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0140-6736(89)90312-7","article-title":"Cytomegalovirus infection and progression towards AIDS in haemophiliacs with human immunodeficiency virus infection","volume":"2","author":"Webster","year":"1989","journal-title":"Lancet"},{"issue":"8477","key":"10.1016\/j.antiviral.2020.104732_bib69","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(86)92315-9","article-title":"Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow","volume":"1","author":"Wimperis","year":"1986","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.antiviral.2020.104732_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev. Med. Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219305066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219305066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:32:39Z","timestamp":1759062759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354219305066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":70,"alternative-id":["S0166354219305066"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104732","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The direct and indirect consequences of cytomegalovirus infection and potential benefits of vaccination","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104732","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104732"}}